I’m still trying to get my head around the Celgene potential $1 billion deal with the Canadian Ontario Institute for Cancer Research (OICR) and Triphase with $40 million up front for TRPH-395 testing. This deal is based on pre-clinical data which has shown broad activity across a range of cancer cell lines (just like 3694???), including in both solid and blood tumors.

Can you imagine (zen3694 started it’s mCRPC clinical trials in June of 2016) $40 million flowing into Zenith right now with the potential of $940 million to come based on future results of it’s mCRPC trial or the TNBC joint trial with Pfizer?

So I’m grasping at straws trying to gain some insight on how this type of deal (Celgene x OICR) gets done. On page 7 of the January 2019 Zenith presentation there is a graph that shows 20 SOC drugs that have varying degrees of synergy with zen3694. This graph illustrates the core of the business strategy going forward.

rndtbl on IV posted that 5 of the drugs on p7 are Pfizer drugs. Don stated that at this stage more than 20 drugs have been tested for synergy. This implies many potential partners for zen3694 testing.

I could not find the legend for the graph and thus I can’t interpret it (perhaps it is just obvious to everyone but me). The scale is between 0 and 1 and on the left the vertical axis is labeled CI Values. Are these confidence interval values and if so how does one interpret them? On the right side there is the word “SYNERGY” with the arrow pointing down. Does this mean the synergy is greater if a drug plots closer to 0?

What do the squares, triangles Xs, etc mean?

I’d like to understand the amount/degree of synergy (magnitude) these drugs have with 3694 given that Zen is entering the collaborative trial on TNBC with Pfizer and the mCRPC trial has included enzalutimide since Dec 2016 (2 years +).

The central questions are;

1. does this graph tell us how strong the interactions are with 3694,
2. can priority targets be set for business and scientific priorities,
3. is there a way to gain some comparison of 3694 results and TRPH-395.

Obviously I’m grasping at straws as to how OICR cut such a brilliant deal. There are many dimensions to this such as the business side, brand credibility, visibility, etc.

What I really like about the Celgene deal is that it illustrates great deals can happen!

As always I'm scratching my head, trying to catch up and figure what I am missing.

Finally, can anyone figure out the symbolism of the apple and orange on page 8 of the January presentation? The communications are not improving. All of the valuable insights come from you incredible posters! Keep it up. Cheers

GLTA

Toinv